10/509078 \$%^STN;HighlightOn=;HighlightOff=;Version Version = STN Express 8.01a; => s 11 SAMPLE SEARCH INITIATED 19:50:22 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE 100.0% PROCESSED 11 ITERATIONS **0** ANSWERS SEARCH TIME: 00.00.01 FULL FILE PROJECTIONS: ONLINE **COMPLETE** **COMPLETE** BATCH PROJECTED ITERATIONS: 22 TO 418 0 ТО PROJECTED ANSWERS: 0 0 SEA SSS SAM L1 L2 => s ll sss full FULL SEARCH INITIATED 19:54:01 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 163 TO ITERATE 100.0% PROCESSED 163 ITERATIONS **19 ANSWERS** SEARCH TIME: 00.00.01 L3 19 SEA SSS FUL L1 => s 13 and nc>1 5300688 NC>1 10 L3 AND NC>1 T.4 => file caplus COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 180.41 180.20 FILE 'CAPLUS' ENTERED AT 19:54:20 ON 20 MAY 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS) Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2007 VOL 146 ISS 22 FILE LAST UPDATED: 18 May 2007 (20070518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


http://www.cas.org/infopolicy.html

=> s 14 L5 7 L4

=> d 15 1-7 bib abs hitstr

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

- AN 2007:82250 CAPLUS
- DN 146:337707
- TI Efficient Syntheses of KDR Kinase Inhibitors Using a Pd-Catalyzed Tandem C-N/Suzuki Coupling as the Key Step
- AU Fang, Yuan-Qing; Karisch, Robert; Lautens, Mark
- CS Davenport Chemistry Laboratories, Department of Chemistry, University of Toronto, Toronto, ON, M5S 3H6, Can.
- SO Journal of Organic Chemistry (2007), 72(4), 1341-1346
- CODEN: JOCEAH; ISSN: 0022-3263
- PB American Chemical Society
- DT Journal
- LA English
- GI
- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- AB A family of four potent KDR kinase inhibitors containing an indol-2-yl quinolin-2-one structure, e.g. I, utilized a Pd-catalyzed tandem C-N and C-C coupling sequence. The key step in preparation of I involved the Pd(OAc)2/(S)-Phos-catalyzed reaction of gem-dibromovinyl compound II with quinoline derivative III to give 86% indol-2-ylquinoline derivative IV. IT 415684-58-1P
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of KDR kinase inhibitors using a Pd-catalyzed tandem C-N/Suzuki
 coupling as the key step)
- RN 415684-58-1 CAPLUS
- CN 2(1H)-Quinolinone, 3-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1Hindol-2-yl]-, hydrochloride (1:1) (CA INDEX NAME)




🕨 нсі

- RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
- AN 2005:172057 CAPLUS
- DN 142:411180
- TI Synthesis of 5-Substituted-1H-indol-2-yl-1H-quinolin-2-ones: A Novel Class of KDR Kinase Inhibitors
- AU Kuethe, Jeffrey T.; Wong, Audrey; Qu, Chuanxing; Smitrovich, Jacqueline; Davies, Ian W.; Hughes, David L.
- CS Department of Process Research, Merck & Co., Inc., Rahway, NJ, 07065, USA SO Journal of Organic Chemistry (2005), 70(7), 2555-2567
- CODEN: JOCEAH; ISSN: 0022-3263
- PB American Chemical Society

DT Journal LA English OS CASREACT 142:411180 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB A number of approaches for the synthesis of the 1H-indol-2-yl-1H-quinolin-2one ring system found in the potent and selective KDR kinase inhibitor I are described. The preparation and reaction of trimethylsilylnitrobenzene II with 2-methoxy-3-quinolinecarboxaldehyde afforded alc. III, which was the key intermediate for the preparation of the target compds. Conversion of alc. III to either nitroketone IV or nitrostyrene V set the stage for reductive cyclization. The quinolin-2-one functionality was unmasked in the last step to provide compound I in 56-60% overall yield from readily available starting materials.
- IT 415684-58-1P RL: SPN (Synthetic preparation); PREP (Preparation) (synthesis of 5-substituted 1H-indol-2-yl-1H-quinolin-2-ones via Fischer-indole cyclization, Pd-catalyzed annulation, and by reductive cyclization of nitro ketone or nitro styrene derivs.)
- RN 415684-58-1 CAPLUS
- CN 2(1H)-Quinolinone, 3-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1Hindol-2-yl]-, hydrochloride (1:1) (CA INDEX NAME)



• нсі

RE.CNT 101 THERE ARE 101 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN AN 2004:857555 CAPLUS DN 141:337784 Formulations for tyrosine kinase inhibitors ΤT Karki, Shyam B.; Deshpande, Sameer R.; Thompson, Karen C.; Payne, Anne H.; ΤN Gandek, Thomas P. Merck & Co. Inc., USA PA SO PCT Int. Appl., 21 pp. CODEN: PIXXD2 DT Patent LA English FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE ---------_____ ------_____ ΡI WO 2004087651 A2 20041014 WO 2004-US8828 20040323 WO 2004087651 A3 20041216 .


PRAI

		₩:	CN,	со,	CR,	AM, CU, HR,	CZ,	DE,	DK,	DM,	DZ,	EC,	ΕE,	EG,	ES,	FI,	GB,	GD,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NI,
			NO,	ΝZ,	OM,	PG,	PH,	ΡL,	РΤ,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			ТJ,	ΤM,	ΤN,	ΤR,	ΤT,	ΤΖ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	SD,	SL,	sΖ,	ΤZ,	UG,	ZM,	ZW,	AM,	ΑΖ,
			BY,	KG,	ΚΖ,	MD,	RU,	ΤJ,	ΤM,	ΑT,	ΒE,	BG,	CH,	CY,	CZ,	DE,	DK,	ΕE,
			ΕS,	FI,	FR,	GB,	GR,	ΗU,	IE,	IΤ,	LU,	MC,	NL,	PL,	ΡТ,	RO,	SE,	SI,
			SK,	ΤR,	BF,	вJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,
			ΤD,															
		2004				A1	-	2004				004-2					0040	
						A1		2001	1014		77 7I	<u> </u>	2519:	106			0040	マクマ
	CA	2519	106					2004										
		2519 1610				A2		2006	0104	1	EP 2	004-	7582	16		2	0040	323
		1610				A2		2006		1	EP 2		7582	16		2		323
	ΕP	1610 R:	614 AT, IE,	BE,	CH, LT,	A2 DE, LV,	DK, FI,	2006 ES, RO,	0104 FR, MK,	GB, CY,	EP 2 GR, AL,	004- IT, TR,	7582: LI, BG,	16 LU, CZ,	NL,	20 SE, HU,	D0403 MC, PL,	323 PT, SK
	EP CN	1610 R: 1764	614 AT, IE, 381	BE, SI,	CH, LT,	A2 DE, LV, A	DK, FI,	2006 ES, RO, 2006	0104 FR, MK, 0426	GB, CY,	EP 2 GR, AL, CN 2	004- IT, TR, 004-8	7582: LI, BG, 8000	16 LU, CZ, 7813	NL, EE,	20 SE, HU, 20	D040 MC, PL, D040	323 PT, SK 323
	EP CN JP	1610 R: 1764 2006	614 AT, IE, 381 5213	BE, SI, 60	CH, LT,	A2 DE, LV, A T	DK, FI,	2006 ES, RO, 2006	0104 FR, MK, 0426 0921	GB, CY,	EP 2 GR, AL, CN 2 JP 2	004- IT, TR, 004-8	7582: LI, BG, 8000 [°] 5074 [°]	16 LU, CZ, 7813 76	NL, EE,	20 SE, HU, 20 20	D040 MC, PL, D040	323 PT, SK 323 323
	EP CN JP US	1610 R: 1764 2006 2006	614 AT, IE, 381 5213 0936	BE, SI, 60	CH, LT,	A2 DE, LV, A T A1	DK, FI,	2006 ES, RO, 2006 2006	0104 FR, MK, 0426 0921 0504	GB, CY,	EP 2 GR, AL, CN 2 JP 2	004- IT, TR, 004-8	7582: LI, BG, 8000 [°] 5074 [°]	16 LU, CZ, 7813 76	NL, EE,	20 SE, HU, 20 20	D040 MC, PL, D040	323 PT, SK 323 323
-	EP CN JP US US	1610 R: 1764 2006	614 AT, IE, 381 5213 0936 -458	BE, SI, 60 66 094P	CH, LT,	A2 DE, LV, A T	DK, FI,	2006 ES, RO, 2006	0104 FR, MK, 0426 0921 0504 0327	GB, CY,	EP 2 GR, AL, CN 2 JP 2	004- IT, TR, 004-8	7582: LI, BG, 8000 [°] 5074 [°]	16 LU, CZ, 7813 76	NL, EE,	20 SE, HU, 20 20	D040 MC, PL, D040	323 PT, SK 323 323

AB The present invention is related to a powder, powder blend or granulation formulation of 3-[5-(4-methanesulfonylpiperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one (I), a tyrosine kinase inhibitor, which is adapted for reconstitution with a diluent. This invention is also related to an aqueous suspension, or a dispersion, particularly to a stable oral pharmaceutical formulation, comprising granules of I mixed with a diluent. Thus, a formulation contained I 1080.0, Avicel PH101 800.0, lactose 1860.0, Klucel EXF 120.0, AcDiSol 120.0, and Mg stearate 20.0 mg/bottle.

IT 415684-58-1P RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (formulations for tyrosine kinase inhibitors)


- RN 415684-58-1 CAPLUS
- CN 2(1H)-Quinolinone, 3-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1Hindol-2-yl]-, hydrochloride (1:1) (CA INDEX NAME)





🕨 нсі

- L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
- AN 2004:804130 CAPLUS
- DN 141:424102
- TI Synthesis of Novel KDR Kinase Inhibitors through Catalytic Reductive Cyclization of o-Nitrobenzylcarbonyl Compounds
- AU Wong, Audrey; Kuethe, Jeffrey T.; Davies, Ian W.; Hughes, David L.
- CS Department of Process Research, Merck & Co., Inc., Rahway, NJ, 07065, USA SO Journal of Organic Chemistry (2004), 69(22), 7761-7764
- CODEN: JOCEAH; ISSN: 0022-3263


PB	American	Chemical	Society
DT	Journal		
LA	English		
OS	CASREACT	141:42410)2
GI			







- AB An efficient synthesis of o-nitrobenzylcarbonyl compds. by the Swern-type oxidation of readily accessible phenethanol analogs is reported. Reductive cyclization of o-nitrobenzylcarbonyl quinoline I [R = 4-(methylsulfonyl)piperazin-1-yl] using catalytic Raney nickel gives 1H-indol-2-yl-1H-quinoline II in 95% yield. Hydrolysis of II affords the KDR kinase inhibitor III in quant. yield. The analogous procedure was applied for the synthesis of indolyl quinolines II (R = H, MeCO2). The examination of the reductive cyclization reaction and optimization of conditions is described.
- IT 415684-58-1P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of indolyl quinolines via catalytic reductive cyclization of nitrobenzylcarbonyl quinolines)
- RN 415684-58-1 CAPLUS
- CN 2(1H)-Quinolinone, 3-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1Hindol-2-yl]-, hydrochloride (1:1) (CA INDEX NAME)




• HCl

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 AN DN TI IN PA SO DT LA	ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN 2003:855752 CAPLUS 139:354459 Solid forms of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2- yl]-1H-quinolin-2-one hydrochloride salt with tyrosine kinase activity Karki, Shyam B.; Payack, Joseph; Treemaneekarn, Varaporn; Wang, Yaling; Sato, Yuichi Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd. PCT Int. Appl., 57 pp. CODEN: PIXXD2 Patent English .CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE												
	-									· 1	•		
L MN.			KIN			APPI	JICAT	ION NO	0.		Dž	ATE	
ΡI	RW:	88900 AE, AG, CO, CR, GM, HR, LT, LU, PL, PT, UA, UG, GH, GM, KG, KZ,	A3 AL, AM, CU, CZ, HU, ID, LV, MA, RO, RU, US, UZ, KE, LS, MD, RU,		0521 AZ, DM, IS, MK, SE, YU, SD, AT,	DZ, EC, JP, KE, MN, MW, SG, SK, ZA, ZM, SL, SZ, BE, BG,	BG, EE, KG, MX, SL, ZW TZ, CH,	BR, 1 ES, 1 KR, 1 MZ, 1 TJ, 1 UG, 1 CY, 0	BY, FI, KZ, NI, TM, ZM, CZ,	BZ, GB, LC, NO, TN, ZW, DE,	CA, GD, LK, NZ, TR, AM, DK,	GE, LR, OM, TT, AZ, EE,	CN, GH, LS, PH, TZ, BY, ES,
PRAI GI		BF, BJ, 25 26051 13577 28400 372782P	CF, CG, A1 A1 A1 T P	CI, CM, 2003 2003 2005 2005 2005	GA, 1030 1103 0526 0922		GW, 2003-2 2003-2 2003-5	ML, 1 24803 22605 50671	MR, 25 1 0	NE,	SN, 20 20 20	TD, 00304 00304	TG 411 411 411


.



- AB The present invention relates to solid forms of the I.HCl of which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals. I and its HCl salt were prepared and crystal forms were obtained and characterized.
- IT 415684-58-1P RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (solid forms of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-

2-yl]-1H-quinolin-2-one hydrochloride salt with tyrosine kinase activity)

- RN 415684-58-1 CAPLUS
- CN 2(1H)-Quinolinone, 3-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1Hindol-2-yl]-, hydrochloride (1:1) (CA INDEX NAME)



HC1


ANSWER 6 OF 7 CAPI	US COP	YRIGHT 2007	ACS on STN		
2003:202621 CAPLUS	:				
138:238027					
Preparation of 3-(2	-indoly	l)quinolin-2	(1H)-ones as	tyrosine k	inase
inhibitors	-			-	
Peckham, Jennifer F	.; Hoff	man, William	F.; Arringt	on, Kenneth	L.; Fraley,
					-
L.	-			1	·
Merck & Co., Inc.,	USA				
PCT Int. Appl., 143	pp.				
CODEN: PIXXD2					
Patent					
English					
CNT 1					
PATENT NO.	KIND	DATE	APPLICATION	NO.	DATE
	2003:202621 CAPLUS 138:238027 Preparation of 3-(2 inhibitors Peckham, Jennifer F Mark E.; Hartman, G L. Merck & Co., Inc., PCT Int. Appl., 143 CODEN: PIXXD2 Patent English CNT 1	2003:202621 CAPLUS 138:238027 Preparation of 3-(2-indoly inhibitors Peckham, Jennifer P.; Hoff Mark E.; Hartman, George D L. Merck & Co., Inc., USA PCT Int. Appl., 143 pp. CODEN: PIXXD2 Patent English CNT 1	2003:202621 CAPLUS 138:238027 Preparation of 3-(2-indolyl)quinolin-2 inhibitors Peckham, Jennifer P.; Hoffman, William Mark E.; Hartman, George D.; Kim, Yunt L. Merck & Co., Inc., USA PCT Int. Appl., 143 pp. CODEN: PIXXD2 Patent English CNT 1	<pre>138:238027 Preparation of 3-(2-indolyl)quinolin-2(1H)-ones as inhibitors Peckham, Jennifer P.; Hoffman, William F.; Arringt Mark E.; Hartman, George D.; Kim, Yuntae; Hanney, T L. Merck & Co., Inc., USA PCT Int. Appl., 143 pp. CODEN: PIXXD2 Patent English CNT 1</pre>	2003:202621 CAPLUS 138:238027 Preparation of 3-(2-indolyl)quinolin-2(1H)-ones as tyrosine k inhibitors Peckham, Jennifer P.; Hoffman, William F.; Arrington, Kenneth Mark E.; Hartman, George D.; Kim, Yuntae; Hanney, Barbara; Sp L. Merck & Co., Inc., USA PCT Int. Appl., 143 pp. CODEN: PIXXD2 Patent English CNT 1

- - - -

PI WO 2003020699 WO 2003020699			A2 A3		2003	0313	1	WO 2	002-1	US27:	114		20	0020	826			
	WÜ	2003	0206	99		AS		2003	0522									
		W :	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑŻ,	BA,	BB,	ΒG,	BR,	ΒY,	ΒŻ,	CA,	CH,	CN,
			co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
				HR,														
			LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	ΟM,	PH,	PL,
			PΤ,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	ΤM,	ΤN,	TR,	ΤT,	ΤZ,	UA,
			UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW							
		RW:	GH,	GM,	ΚĖ,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	ΤZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
			KG,	ΚŻ,	MD,	RU,	ΤJ,	ΤM,	ΑT,	ΒE,	ВG,	CH,	CY,	CZ,	DE,	DK,	ΕĒ,	ES,
			FΙ,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	ΡT,	SE,	SK,	ΤR,	BF,	ΒJ,	CF,
			CG,	CI,	CM,	GA,	GN,	GQ,	G₩,	ML,	MR,	ΝE,	SN,	ΤD,	ΤG			
	AU	2002	3234	06		A1		2003	0318		AU 2	002-3	3234	06		20	0020	826
	US	2004	2358	26		A1		2004	1125		US 2	004-	4875	89		21	00403	224
	US	7186	723			в2		2007	0306									
PRAI	US	2001	-316	123P		Ρ		2001	0830									
	WO	2002	-US2	7114		W		2002	0826									
GI																		

Ι

 $(R^{1})_{m}$ $(R^{1})_{m}$ $(R^{1})_{m}$ $(R^{1})_{m}$ $(R^{2})_{n}$ $(R^{4})_{n}$ $(R^{4})_{n}$




Title compds., including I (R groups undefined), were prepared and ÅВ inhibitors, regulators, and/or modulators of tyrosine kinase signal transduction. For example, 1-(tert-butoxycarbonyl)-5-[(tertbutyldimethylsilyl)oxy]-1H-indol-2-ylboronic acid was coupled with 2-chloro-3-iodoquinoline (preparation of starting materials given) in the presence of Pd(PPh3)4 and K3PO4 in dioxane to give the protected 3-(2-indolyl)quinoline derivative Deprotection using triethylamine trihydrofluoride afforded the alc. Reaction with 1-(2chloroethyl)piperidine•HCl and Cs2CO3 in DMF followed by reflux at 110° in AcOH and H2O for 12 h provided II. Compds. of the invention inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.01 μ M - 5.0 μ M. Thus, I and compns. containing I are useful for the treatment of tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).

IT 501334-36-7P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (tyrosine kinase inhibitor; preparation of (indolyl)quinolinones for treatment of cancer, atherosclerosis, inflammatory diseases, and other tyrosine kinase-dependent conditions) RN 501334-36-7 CAPLUS CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4 (methylsulfonyl)-, 1-oxide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 335649-91-7 CMF C23 H24 N4 O4 S




CM 2

CRN 76-05-1 CMF C2 H F3 O2

F - с- со2н F F

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN AN 2002:314903 CAPLUS DN 136:325437 ΤI Preparation of oxoquinolinylindole-5-methanamine salts as tyrosine kinase signal transduction modulators Fraley, Mark E.; Karki, Shyam B.; Kim, Yuntae ΙN Merck & Co., Inc., USA ΡA PCT Int. Appl., 73 pp. SO CODEN: PIXXD2 DT Patent English LA FAN.CNT 1 KIND APPLICATION NO. PATENT NO. DATE DATE _____ _____ ____ -----_____ WO 2002032861 WO 2001-US32508 ΡI A2 20020425 20011017 WO 2002032861 A3 20020815 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,

			RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	тJ,	, TM,	TR,	ΤT,	ΤZ,	UA,	UG,	US,
			UΖ,	VN,	YU,	ZA,	ZW											
		RW:	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	, ΤΖ,	UG,	ZW,	ΑT,	ΒE,	CH,	CY,
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	, LU,	MC,	NL,	PΤ,	SE,	ΤR,	BF,
			BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	, ML,	MR,	NE,	SN,	ΤD,	ΤG	
	CA	2424	689			A1		2002	0425		CA 2	2001-3	2424	689		20	00110)17
	AU	2002	0268	77		A5		2002	0429		AU 2	2002-2	2687	7		20	00110)17
	US	2002	07252	26				2002	0613		US 2	2001-	9819	79		20	00110	017
	US	6656	942			B2		2003	1202									
	ΕP	1328	519			A2		2003	0723		EP 2	2001-	9877	42		20	00110)17
	ΕP	1328	519			B1		2005	0907									
		R:	ΑT,	ΒE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	, IT,	LI,	LU,	NL,	SE,	MC,	ΡT,
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	, TR						
	JP	2004	5115	41		Т		2004	0415		JP 2	2002-	5360	45		20	00110	017
	AΤ	3039	98			Т		2005	0915		AT 2	2001-	9877	42		20	00110	017
	ES	2247	187			ΤЗ		2006	0301	•	ES 2	2001-1	1987	742		20	00110	017
	US	2004	00250	01		A1		2004	0101		US 2	2003-3	3988	51		20	00304	110
	US	6960	590			В2		2005	1101									
PRAI	US	2000	-2410	043P		Р		2000	1017									
	WO	2001	-US32	2508		W		2001	1017									
GI																		




- AB Title compds. were prepared as tyrosine kinase signal transduction modulators (no data). Thus, di-protected 5-hydroxymethylindole-2-boronic acid was condensed with 3-iodo-2-quinolinone (preparation each given) and the O-deprotected product oxidized to the aldehyde which was reductively aminated by 1-methanesulfonylpiperazine to give, after deprotection and salt formation, title compound I.MeSO3H.
- IT 415684-56-9P 415684-57-0P 415684-58-1P 415684-59-2P 415684-60-5P 415684-61-6P 415684-62-7P 415684-63-8P 415684-64-9P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of oxoquinolinylindole-5-methanamine salts as tyrosine kinase signal transduction modulators)
- RN 415684-56-9 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 335649-90-6

CMF C23 H24 N4 O3 S



СМ 2 CRN 75-75-2 CMF C H4 O3 S




- RN
- 415684-57-0 CAPLUS Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX CN NAME)

.

СМ 1


CRN 335649-90-6 CMF C23 H24 N4 O3 S




2 СМ

CRN 87-69-4 CMF C4 H6 O6

Absolute stereochemistry.




```
RN 415684-58-1 CAPLUS
CN
     2(1H)-Quinolinone, 3-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1H-
     indol-2-yl]-, hydrochloride (1:1) (CA INDEX NAME)
```



- RN
- 415684-59-2 CAPLUS Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-CN (methylsulfonyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)
 - СМ 1

CRN 335649-90-6 CMF C23 H24 N4 O3 S




СМ 2

CRN 77-92-9 CMF C6 H8 O7

RN 415684-60-5 CAPLUS CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, monoacetate (9CI) (CA INDEX NAME)


СМ 1 CRN 335649-90-6 CMF C23 H24 N4 O3 S



CM 2

CRN 64-19-7 CMF C2 H4 O2

RN 415684-61-6 CAPLUS CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, monohydrobromide (9CI) (CA INDEX NAME)




• HBr

RN 415684-62-7 CAPLUS

CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)


CM 1

CRN 335649-90-6 CMF C23 H24 N4 O3 S



CM 2 CRN 110-16-7 CMF C4 H4 O4


Double bond geometry as shown.



- RN 415684-63-8 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 335649-90-6 CMF C23 H24 N4 O3 S



CM 2 CRN 7664-93-9 CMF H2 O4 S




RN 415684-64-9 CAPLUS CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-

```
(methylsulfonyl)-, monobenzenesulfonate (9CI) (CA INDEX NAME)
```


CM 1

CRN 335649-90-6 CMF C23 H24 N4 O3 S






CRN 98-11-3 CMF C6 H6 O3 S




=> d his (FILE 'HOME' ENTERED AT 19:49:26 ON 20 MAY 2007) FILE 'REGISTRY' ENTERED AT 19:49:46 ON 20 MAY 2007 L1STRUCTURE UPLOADED 0 S L1 L2 L3 19 S L1 SSS FULL 10 S L3 AND NC>1 L4FILE 'CAPLUS' ENTERED AT 19:54:20 ON 20 MAY 2007 7 S L4 L5 => s 13 not 14 15 L3 7 L4 L6 8 L3 NOT L4 => d 16 1-8 bib abs hitstr L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN 2006:437069 CAPLUS AN 144:468020 DN ΤI Process for preparation of 2-substituted indoles from dihalovinylanilines and organoboron reagents. IN Lautens, Mark; Fang, Yuanqing PA Can.

SO		[Int DEN:		• •	172	pp.												
DT		tent																
LA	Eng	glish																
FAN.CNT 1																		
	PATENT NO. KIND DATE APPLICATION NO.									D	ATE							
PI	 WO	2006	0478	88		A1		2006	0511	I	NO 2	005-0	CA17	03		2	0051	104
								AU,										
								DE,										
			GE,	GH,	GM,	HR,	нU,	ID,	IL,	IN,	IS,	J₽,	KΕ,	KG,	KΜ,	KN,	KΡ,	KR,
			ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
			•	•	-			ΝZ,										
								ΤJ,	ΤM,	ΤN,	ΤR,	ΤT,	ΤΖ,	UA,	UG,	US,	UZ,	VC,
			,	YU,	•	,		0.7		DV		50			C D	C D		T 17
		RW:	•	•	•			CZ,			•		•				-	
				•	•	•	•	MC,	•				•	•		•		
						•		GN, NA,		•								
				KZ,		•			50,	<u>о</u> ш,	54,	10,	00,	<i>2</i> ,	211,	<i>P</i> 111,	ΠΔ ι	ы,
PRAT	US	2004		•					1105									
US 2005-662797P P 20050318																		
US 2005-662797P P 20050318 OS MARPAT 144:468020 GI																		



AB	Title compds. [I; R2 = H, (substituted) alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl; R3 = H, (substituted) alkyl,
	haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl,
	aralkyl, heteroaralkyl; R4 = (substituted) mono- or polycyclic aryl,
	heteroaryl, alkyl, alkenyl bonded to the 2-position of the indole ring via
	a C-C bond] were prepared by reaction of ortho-dihalovinylanilines (II; X =
	Br, Cl, iodo; R2, R3 as above) with boronic esters, boronic acids, boronic
	acid anhydrides, trialkylboranes, or 9-BBN derivs. of R4 in the presence
	of base, Pd metal precatalyst, and a ligand. Thus, 2-(2,2-
	dibromovinyl)phenylamine, PhB(OH)2, K3PO4.H2O, Pd(OAc)2, and s-Phos were
	heated in PhMe at 90° for 6 h to give 84% 2-phenylindole.
ΙT	335649-90-6P
	RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
	(Preparation)
	(process for preparation of substituted indoles from dihalovinylanilines and organoboron reagents)
RN	335649-90-6 CAPLUS


CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




- RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
- AN 2005:571929 CAPLUS
- DN 143:298428
- TI Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: Differential effects in vitro and in vivo on mRNA and functional activity
- AU Gibson, Christopher R.; Lin, Charles; Singh, Rominder; Brown, Cheri M.; Richards, Karen; Brunner, Janice; Michel, Kimberly; Adelsberger, Jennifer; Carlini, Edward; Boothe-Genthe, Catherine; Raab, Conrad; Luu, Minh; Michael, Aimee; Parikh, Mona; Ciecko, Patrice; Subramanian, Raju; Krolikowski, Paul; Rodrigues, A. David; Baillie, Thomas A.; Rushmore, Thomas H.
- CS Department of Drug Metabolism, Merck Research Laboratories, West Point, PA, USA
- SO Drug Metabolism and Disposition (2005), 33(7), 1044-1051 CODEN: DMDSAI; ISSN: 0090-9556
- PB American Society for Pharmacology and Experimental Therapeutics
- DT Journal
- LA English
- AB Compound I [3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1Hquinolin-2-one] is a potent inhibitor of human kinase insert domain-containing receptor (KDR kinase), which is under investigation for the treatment of cancer. Bile duct-cannulated male beagle dogs were administered 6 mg/kg compound I q.d. for 14 days. There was an approx. 2.5-fold decrease in the mean plasma area under the curve of I on days 7 and 14 (.apprx.11.3 µM - h), relative to day 1 (28.2 µM - h). In the dog, compound I was eliminated by metabolism, with a major pathway being aromatic

compound I was eliminated by metabolism, with a major pathway being aromatic hydroxylation and subsequent sulfation to form the metabolite M3. Metabolic profiling suggested that the pathway leading to the formation of the sulfated conjugate M3 was induced upon multiple dosing of I. Studies conducted in vitro suggested that CYPIA1/2 was responsible for the formation of the hydroxylated metabolite, which is sulfated to yield M3. Addnl. studies confirmed induction of CYPIA protein and activity in the livers of dogs treated with I. However, studies in a dog hepatocyte model of induction showed a surprising decrease both in CYPIA mRNA and enzymic activity in the presence of I, emphasizing the need to consider the results from a variety of in vitro and in vivo studies in deriving an understanding of the metabolic fate of a drug candidate. It is concluded that the autoinduction observed after multiple treatments with compound I occurs since compound I is both an inducer and a substrate for dog CYPIA. 335649-90-6D, oxygenated 335649-91-7 864852-18-6


- IT 335649-90-6D, oxygenated 335649-91-7 864852-18-6 864852-20-0 864852-22-2 864852-29-9 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CYP1A activity and mechanism of kinase insert domain-containing receptor inhibitors pharmacokinetics in dog)
- RN 335649-90-6 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




- RN 335649-91-7 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 864852-18-6 CAPLUS
CN Piperazine, 1-[[2-[1,2-dihydro-2-oxo-8-(sulfooxy)-3-quinolinyl]-1H-indol-5yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 864852-20-0 CAPLUS
CN Piperazine, 1-[[2-[1,2-dihydro-2-oxo-6-(sulfooxy)-3-quinolinyl]-1H-indol-5yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 864852-22-2 CAPLUS CN 2(1H)-Quinolinone, 6-hydroxy-3-[5-[[4-(methylsulfonyl)-1-


piperazinyl]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 864852-29-9 CAPLUS CN 2(1H)-Quinolinone, 8-hydroxy-3-[5-[[4-(methylsulfonyl)-1piperazinyl]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



- IT 335649-90-6, [3-[5-(4-Methanesulfonyl-piperazin-1-ylmethyl)-1Hindol-2-yl]-1H-quinolin-2-one] RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (CYP1A activity and mechanism of kinase insert domain-containing receptor inhibitors pharmacokinetics in dog)
- RN 335649-90-6 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



- RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
- AN 2005:174313 CAPLUS
- DN 142:309130
- TI Concerns in the development of an assay for determination of a highly conjugated adsorption-prone compound in human urine
- AU Xu, Yang; Du, Lihong; Rose, Mark J.; Fu, Irong; Woolf, Eric J.; Musson, Donald G.
- CS Merck Research Laboratories, West Point, PA, 19486, USA


- SO Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2005), 818(2), 241-248 CODEN: JCBAAI; ISSN: 1570-0232
- ΡB Elsevier B.V.
- DTJournal
- LA English
- AB Concerns in pre-anal. handling of urine samples are discussed using a new KDR kinase inhibitor, 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1Hindol-2-yl]-1H-quinolin-2-one (compound A), as an example of a case where high light sensitivity and low analyte recovery (high affinity for container surface) were found. The absence of these problems in plasma samples may be a result of the plasma protein content. Low recovery of the analyte from urine can be remedied by either changing the container or by using additives, such as bovine serum albumin (BSA) or non-ionic surfactant Tween-20. In the case of compound A, changing containers (polypropylene vs. glass vial) or addition of BSA did bring analyte recovery up to 80%. However, the addition of 0.2% Tween-20 into urine quality controls (QCs) gave more than 95% analyte recovery, indicating effective reduction of analyte loss to the surface of containers. The urine assay using mixed-mode SPE and LC-MS/MS was not affected significantly by introducing Tween-20 into the samples. The mean SPE extraction recovery was 68.4% and matrix suppression of ionization on MS was less than 8% at all analyte concns. The linear range of the calibration curve was 0.5-400 ng/mL on PE Sciex API 3000 LC-MS/MS system. The assay intraday accuracy and precision were 92.1-104.8% and <4.2% (%CV), resp. Urine QC samples, containing 0.2% Tween-20, gave excellent recovery after three cycles of freeze and thaw. Since analyte loss to its urine container surface is not unique to compound A (M. Schwartz, W. Kline, B. Matuszewski, Anal. Chim. Acta 352 (1997) 299-307; A. L. Fisher, E. DePuy, T. Shih, R. Stearns, Y. Lee, K. Gottesdiener, S. Flattery, M. De Smet, B. Keymeulen, D. G. Musson, J. Pharm. Biomed. Anal. 26 (2001) 739-752), we suggest an evaluation of the potential problem in the early stages of urine assay development to ensure reliable quantitation of analytes. The addition of Tween-20 can serve as a useful anal. tool to other analytes with similar situations. IT 335649-90-6, 3-[5-(4-Methanesulfonyl-piperazin-1-ylmethyl)-1H-

indol-2-yl]-1H-quinolin-2-one

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(concerns in development of an assay for determination of highly conjugated adsorption-prone compound in human urine)

- RN 335649-90-6 CAPLUS
- Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-CN (methylsulfonyl) - (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

Lб ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN


AN 2005:85916 CAPLUS

DN 142:328833

Simultaneous determination of a novel KDR kinase inhibitor and its N-oxide ΤI


metabolite in human plasma using 96-well solid-phase extraction and liquid chromatography/tandem mass spectrometry Xu, Yang; Du, Lihong; Soli, Eric D.; Braun, Matthew P.; Dean, Dennis C.; AU Musson, Donald G. CS Merck Research Laboratories, Department of Drug Metabolism, West Point, PA, 19486, USA Journal of Chromatography, B: Analytical Technologies in the Biomedical SO and Life Sciences (2005), 817(2), 287-296 CODEN: JCBAAI; ISSN: 1570-0232 PB Elsevier B.V. DT Journal English LA To support pharmacokinetic studies, a selective and sensitive liquid AB chromatog./tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of a novel KDR kinase inhibitor (1)and its active metabolite (2) in human plasma. The method is fully automated using a Packard MultiPROBE II system and a TomTec Quadra 96 liquid handling workstation to perform sample preparation and solid-phase extraction (SPE). Following the extraction on a mixed-mode SPE using Oasis MCX 96-well plate, the analytes were separated on a Aquasil C18 column (50 mm \times 2.1 mm, i.d., 3 $\mu m)$ with a mobile phase consisting of acetonitrile/ammonium acetate buffer (5 mM, pH 5.0) (60/40, volume/volume). The run time for each injection was 4.5 min with the retention times of approx. 2.0 and 2.7 min for 1 and 2 resp., at a flow rate of 0.25 mL/min. A tandem mass spectrometric detection was conducted using multiple reaction monitoring (MRM) under the pos. ion mode with a turbo ion-spray interface. The linear ranges of the calibration curves were 0.05-400 ng/mL for 1 and 0.1-400 ng/mL for 2 on a PE Sciex API 4000 LC-MS/MS system. The lower limits of quantitation (LLOQ) of the assay were 0.05 and 0.1 ng/mL for 1 and 2 resp., when 0.4 mL of plasma was processed. Intra-day assay precision (using 5 standard curves prepared by spiking compds. to 5 lots of plasma) was < 4.9% for 1 and < 9.6%for 2 on each concentration Assay accuracy was found to be 95.1-104.6% of nominal for 1 stds. and 93.5-105.6% for 2 stds. QC samples were stable when kept at room temperature for 4 h, at -70 $^\circ C$ for 10 days, and after 3 freeze-thaw cycles. The extraction recoveries were 80, 83, and 84% for 1 and 2 and I.S. resp., and no significant matrix effects were observed The method was successfully applied to plasma samples from clin. studies after oral administration of compound 1. 335649-90-6 335649-91-7 IΤ RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (simultaneous determination of novel KDR kinase inhibitor and its N-oxide metabolite in human plasma by LC-MS/MS)

- RN 335649-90-6 CAPLUS
- Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-CN (methylsulfonyl) - (9CI) (CA INDEX NAME)



- RN 335649-91-7 CAPLUS
- Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-CN

(methylsulfonyl)-, 1-oxide (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN L6

- AN 2005:14366 CAPLUS
- 142:113888 DN
- Substituted indoles and a process for their preparation via ΤI Pd/diamine-catalyzed reductive cyclization of ortho-nitrostyrenes under CO pressure
- Davies, Ian W.; Smitrovich, Jacqueline H.; Qu, Chuanxing Merck & Co., Inc., USA IN
- PA
- PCT Int. Appl., 31 pp. SO
- CODEN: PIXXD2
- DT Patent
- LA English
- FAN.CNT 1

	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI	WO 2005000804 WO 2005000804		WO 2004-US17357	20040601
	CN, CO, CR, GE, GH, GM, LK, LR, LS, NO, NZ, OM, TJ, TM, TN, RW: BW, GH, GM, AZ, BY, KG, EE, ES, FI,	CU, CZ, DE, DK, HR, HU, ID, IL, LT, LU, LV, MA, PG, PH, PL, PT, TR, TT, TZ, UA, KE, LS, MW, MZ, KZ, MD, RU, TJ, FR, GB, GR, HU,	 BA, BB, BG, BR, BW, BY DM, DZ, EC, EE, EG, ES IN, IS, JP, KE, KG, KP MD, MG, MK, MN, MW, MX RO, RU, SC, SD, SE, SG UG, US, UZ, VC, VN, YU NA, SD, SL, SZ, TZ, UG TM, AT, BE, BG, CH, CY IE, IT, LU, MC, NL, PL CI, CM, GA, GN, GQ, GW 	, FI, GB, GD, , KR, KZ, LC, , MZ, NA, NI, , SK, SL, SY, , ZA, ZM, ZW , ZM, ZW, AM, , CZ, DE, DK, , PT, RO, SE,
PRAI OS GI	SN, TD, TG AU 2004251175 CA 2526988 EP 1633694 R: AT, BE, CH, IE, SI, LT, CN 1798726	A1 20050106 A1 20050106 A2 20060315 DE, DK, ES, FR, LV, FI, RO, MK, A 20060705 T 20061124 A1 20070308 P 20030605 W 20040601	AU 2004-251175 CA 2004-2526988 EP 2004-776226 GB, GR, IT, LI, LU, NL CY, AL, TR, BG, CZ, EE CN 2004-80015534 JP 2006-515094 US 2005-557537	20040601 20040601 20040601 , SE, MC, PT, , HU, PL, SK, HR 20040601 20040601

.




AB The invention is directed to novel compds. I and II as well as a process for the preparation of II from I, via palladium-catalyzed reductive cyclization of I under CO pressure with aromatic diamines as ligands, wherein RI = H, (un)substituted alkyl or alkoxy; R2 = H, (un)substituted alkyl, alkoxy or halo; R3 = H, (un)substituted alkyl or alkoxy; R2 and R3 can link together; R4 = H, (un)substituted alkyl, alkoxy or ester; R5 = (un)substituted alk(en/yn)yl, (hetero)aryl, amide or ketone; R = H or OH; or salts thereof. For example, An autoclave was charged with III (15 g, preparation given), Pd(OTf)2 (0.020 g), 3,4,7,8-tetramethyl-1,10-phenathroline (0.102 g) and DMF (100 mL). After the vessel was purged three times successively with N2 and CO, the reactor was pressurized to 15 psig with CO and aged at 70 °C for 14 h. IV was isolated in 83 % yield after work-up. The new process can be conducted under milder conditions, such as lower temperature and CO pressure, as well as lower catalyst and ligand loading, which simplify purification II are useful intermediates of pharmaceutical compds., such as KDR inhibitors and GNRH inhibitors (no data).

IT 335649-90-6P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(target; preparation of indoles via Pd/diamine-catalyzed reductive cyclization of ortho-nitrostyrenes under CO pressure)

- RN 335649-90-6 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L6

GI

ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN AN 2004:1005650 CAPLUS DN 142:134559 ΤI A Concise Synthesis of a Novel Antiangiogenic Tyrosine Kinase Inhibitor AU Payack, Joseph F.; Vazquez, Enrique; Matty, Louis; Kress, Michael H.; McNamara, James CS Department of Process Research, Merck & Co. Inc., Rahway, NJ, 07065-0900, USA SO Journal of Organic Chemistry (2005), 70(1), 175-178 CODEN: JOCEAH; ISSN: 0022-3263 ΡB American Chemical Society DT Journal LA English CASREACT 142:134559 OS

- Boc 0 Ι II
- Antiangiogenic compound I (R = H; R1 = MeSO2) (an inhibitor of the AB endothelial VEGF receptor KDR) is prepared concisely and efficiently on kilogram scale using the Suzuki-Miyaura coupling of a boronic acid generated in situ from Boc-protected indolemethylpiperazine II (Boc = Me3COCO) with 3-bromoquinolin-2-one as the key step. 5-Cyanoindole is Boc protected at the indole nitrogen, reduced to the aldehyde with DIBAL, and reductively aminated with Boc-piperazine using sodium triacetoxyborohydride to yield II. Methyltrioxorhenium-mediated oxidation of 3-bromoquinoline followed by rearrangement of the N-oxide with p-toluenesulfonyl chloride yields 3-bromoquinolin-2-one. Lithiation of II with LDA at <5° followed by addition of triisopropyl borate and quenching with hydrochloric acid yields a 2-indoleboronic acid which is coupled with 3-bromoquinolin-2-one in the presence of palladium acetate, triphenylphosphine, and dicyclohexylamine to yield I (R = R1 = Boc) in 88% yield. Cleavage of the Boc groups with hydrochloric acid followed by mesylation of the piperazine yields I (R = H; R1 = MeSO2).


IT 335649-90-6P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(concise preparation of an antiangiogenic compound on kilogram scale using a Suzuki-Miyaura coupling of an indoleboronic acid (generated in situ) and a bromoquinolinone as the key step)

```
335649-90-6 CAPLUS
RN
```

Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-CN (methylsulfonyl) - (9CI) (CA INDEX NAME)



THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 14 ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN L6

2003:202476 CAPLUS AN

- DN 138:238026
- ΤI Preparation of indolinylquinolinones as tyrosine kinase inhibitors with therapeutic uses
- IN Kim, Yuntae; Hanney, Barbara; Spencer, Keith L.; Hartman, George D.; Arrington, Kenneth L.
- ΡA Merck & Co., Inc., USA
- PCT Int. Appl., 90 pp. SO
- CODEN: PIXXD2
- DT Patent
- English LA
- FAN.CNT 1 PATENT NO

L'AN.	PATENT	NO.			KIN	D	DATE		i	APPL	ICAT	ION	NO.		Dž	ATE	
PI	WO 2003	0202	76		A1		2003	0313	I	NO 2	002-	JS27	161		2	0020	826
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	ΒA,	ΒB,	ΒG,	BR,	ΒY,	ΒΖ,	CA,	CH,	CN,
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	ΕE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KR,	KΖ,	LC,	LK,	LR,	LS,
		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	OM,	PH,	ΡL,
		ΡT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	ΤM,	ΤN,	ΤR,	ΤT,	ΤZ,	UA,
	UG, US, UZ				VC,	VN,	YU,	ZA,	ZM,	ZW							
	RW:	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	ΤZ,	UG,	ZM,	ZW,	ΑT,	ΒE,	BG,
		CH,	CY,	CZ,	DE,	DK,	ΕE,	ES,	FI,	FR,	GB,	GR,	IΕ,	IΤ,	LU,	MC,	NL,
		ΡT,	SE,	SK,	ΤR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,
		NE,	SN,	ΤD,	ΤG												
	AU 2002	32670	60		A1		2003	0318	i	AU 2	002-	3267	60		2	0020	826
	US 2004	19272	25		A1		2004	0930	1	US 2	004-	4875	88		2	0040	224
US 6927293					B2		2005	0809									
PRAI	US 2001	-3158	897P		P		2001	0830									
	WO 2002		W		2002	0826											
OS	MARPAT	138:2	2380	26													

GI




AB The present invention relates to indolinylquinolinones (shown as I; variables defined below; e.g. 3-[6-[(4-methylpiperazin-1-yl)carbonyl]-1Hindol-2-yl]quinolin-2(1H)-one) which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals. For I: a = 0 or 1; b = 0 or 1; n = 0, 1, or 2; t = 1 or 2; R1 and R5 = H, (C:O)aObC1-C10 alkyl, (C:O)aObaryl, (C:O)aObC2-C10 alkenyl, (C:O)aObC2-C10 alkynyl, CO2H, halo, OH, ObC1-C6 perfluoroalkyl, (C:O)aNR7R8, CN, (C:O)aObC3-C8 cycloalkyl, and (C:O)aObheterocyclyl. R2 and R3 = H, (C:O)OaC1-C6 alkyl, (C:O)Oaaryl, C1-C6 alkyl, SO2Ra, and aryl; R4a or R4b = H and the other = (C:O)aObC1-C10 alkyl, (C:O)aObaryl, (C:O)aObC2-C10 alkenyl, (C:O)aObC2-C10 alkynyl, CO2H, halo, OH, ObC1-C6 perfluoroalkyl, (C:O)aNR7R8, CN, (C:O)aObC3-C8 cycloalkyl, and (C:O)aObheterocyclyl. R7 and R8 = H, (C:O)ObC1-C10 alkyl, (C:O)ObC3-C8 cycloalkyl, (C:O)Obaryl, (C:O)Obheterocyclyl, C1-C10 alkyl, aryl, C2-C10 alkenyl, C2-C10 alkynyl, heterocyclyl, C3-C8 cycloalkyl, SO2Ra, (C:O)N(Rb)2, or R7 and R8 can be taken together with the N to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the N, one or two addnl. heteroatoms = N, O and S;

Ra


= (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, or heterocyclyl; and Rb is H, (C1-C6)alkyl, aryl, heterocyclyl, (C3-C6)cycloalkyl, (C:O)OC1-C6 alkyl, (C:O)C1-C6 alkyl or S(O)2Ra. Compds. I inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values = 0.01-5.0 μ M. Although the methods of preparation are not claimed, 3 example prepns. are included.

- IT 501364-54-1P, 3-[3-Fluoro-5-(4-methanesulfonylpiperazin-1ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of indolinylquinolinones as tyrosine kinase inhibitors with therapeutic uses)
- RN 501364-54-1 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-3-fluoro-1H-indol-5yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



- IT 335649-90-6, 3-[5-[[4-(Methylsulfonyl)piperazin-1-yl]methyl]-1Hindol-2-yl]quinolin-2(1H)-one RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of indolinylquinolinones as tyrosine kinase inhibitors with therapeutic uses)
- RN 335649-90-6 CAPLUS

CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

LG	ANSWER				JS (COPY	RIGH	T 20	07 A	CS OI	n STI	N					
AN	2001:30		CA	PLUS													
DN	134:326																
ΤI	Prepara inhibit		of	3-(2	-ind	olyl)qui:	noli	ne-2	-one	der.	ivat:	ives	as	tyro	sine	kinase
IN	Arringt D.; Hof											-			Hartı	nan,	George
PA	Merck &	Co.	, In	c., 1	USA		-										
SO	PCT Int	. Ap	pl.,	130	pp.												
	CODEN:	-	. .		+ +												
DT	Patent																
LA	English	1															
	CNT 1	•															
	PATENT	NO.			KIN	D	DATE		i	APPL	ICAT	ION	NO.		Dž	ATE	
ΡI	WO 2001	0290	25		 A2	-	2001	0426	, I	WO 2	000-	US28	625		20	0001	016
	WO 2001	0290	25		A3			1101									
	W:			AL,					BA.	BB.	BG.	BR.	BY.	BZ.	CA.	CH.	CN.
				CZ,													
			-	IL,		-											-
			•	MD,				•		-	-				-		-
				SI,	•			•				-	-	•	•	•	•
		ZA,		51,	51,	υц,	10,	111,	11()	11,	10,	UA,	00,	05,	02,	v Iv ,	10,
					τc	MIAT	M7	SD	ст	C7	TT 7		7 147	አጥ	DD	CH	CV
	DIA.	CU	CM														
	RW:	GH,	•											-	-		-
	RW:	DE,	DK,	KE, ES, CI,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PΤ,	-		-

~ ~ . .

	CA	2387351	A1	20010426	CA 2000-2387351	20001016
	BR	2000014843	А	20020611	BR 2000-14843	20001016
	ΕP	1226136	A2	20020731	EP 2000-978230	20001016
	ĒΡ	1226136	В1	20041229		
		R: AT, BE, CH,	DE,	DK, ES, FR,	GB, GR, IT, LI, LU, NL,	SE, MC, PT,
		IE, SI, LT,	LV,	FI, RO, MK,	CY, AL	
	ΤR	200201051	Т2	20020923	TR 2002-1051	20001016
	HU	200203323	A2	20030228	HU 2002-3323	20001016
	JP	2003512369	Т	20030402	JP 2001-531825	20001016
	JP	3822494	B2	20060920		
	ΕE	200200201	А	20030616	EE 2002-201	20001016
	ΝZ	518001	А	20040528	NZ 2000-518001	20001016
		778588	В2	20041209	AU 2001-15710	20001016
		286045	Т	20050115	AT 2000-978230	20001016
		1226136	Т	20050429	PT 2000-978230	20001016
		2234698	ТЗ	20050701	ES 2000-978230	20001016
		6306874	В1	20011023	US 2000-690598	20001017
		239957	В	20050921	TW 2000-89121943	20001019
		2002002985	А	20030416	ZA 2002-2985	20020416
		2002001820	А	20020523	NO 2002-1820	20020418
		6794393	В1	20040921	US 2002-110872	20020418
		106710	А	20030331	BG 2002-106710	20020516
		1054931	A1	20060317	HK 2003-107148	20031003
		2005096344	A1	20050505	US 2004-900662	20040728
		2006206609	А	20060810	JP 2006-127244	20060501
PRAI		1999-160356P	Ρ	19991019		
		2001-531825	A3	20001016		
	-	2000-US28625	W	20001016		
		2000-690598	A	20001017		
		2002-110872	A1	20020418		
OS	MAF	RPAT 134:326411				

OS GI




AB Title compds. [I; R = (CH3)2NCH2CH(CH3)CH2O, (CH3OCH2CH2)(C6H5CH2)NCH2CH2O , (CH3CH2)2NCH2CH2O, (CH3)(C6H5CH2)NCH2CH2CH2O, (CH3OCH2CH2)(HOOCCH2CH2)NCH2CH2O, (CH3OCH2CH2)(CH3SO2)NCH2, cycloalkylaminoalkyl, heterocyclylalkyl, etc.], stereoisomer, and pharmaceutically acceptable salts are prepared and inhibit, regulate and/or modulate tyrosine kinase signal transduction. Title compds. are tested on

IT


VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.001-5.0 μ M. Pharmaceutical compns. and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, etc. are discussed. Thus, the title compound II was prepared 335649-91-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 3-(2-indolyl)quinoline-2-one derivs. as tyrosine kinase inhibitors)

- RN 335649-91-7 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)-, 1-oxide (9CI) (CA INDEX NAME)



- IT 335649-90-6P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of 3-(2-indolyl)quinoline-2-one derivs. as tyrosine kinase inhibitors)
- RN 335649-90-6 CAPLUS
- CN Piperazine, 1-[[2-(1,2-dihydro-2-oxo-3-quinolinyl)-1H-indol-5-yl]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



=> log h COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 81.87	SESSION 262.28
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.70	-11.70

SESSION WILL BE HELD FOR 120 MINUTES STN INTERNATIONAL SESSION SUSPENDED AT 19:57:59 ON 20 MAY 2007